Johnson & Johnson Innovative Medicine discovers, develops, and commercializes advanced biologics, cell‑based and precision‑medicine therapies across oncology, immunology, neuroscience, and cardiopulmonary diseases. Leveraging a global research network, extensive clinical‑trial infrastructure, and partnerships with biotech and academic innovators, it accelerates the delivery of targeted treatments to physicians and patients worldwide.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with complex, high‑need diseases often lack effective, less‑invasive treatment options, and clinicians need access to innovative therapies that can improve outcomes while minimizing side effects.
Solution
Johnson & Johnson Innovative Medicine leverages a global research network and deep scientific expertise to discover, develop, and commercialize new medicines and medical technologies across oncology, immunology, neuroscience, and cardiopulmonary areas. The organization integrates advanced biologics, cell‑based therapies, and precision‑medicine approaches with a robust clinical‑trial infrastructure to accelerate the translation of discoveries into approved products. By partnering with external innovators and employing state‑of‑the‑art manufacturing and regulatory capabilities, it brings novel, targeted treatments to market faster, expanding therapeutic options for patients and supporting clinicians in delivering personalized care.
Target Audience
Primary customers are physicians and healthcare systems seeking cutting‑edge therapies for oncology, immunology, neuroscience, and cardiopulmonary diseases, as well as patients requiring advanced treatment options.
Features
- Integrated pipeline spanning early discovery to late‑stage clinical development in multiple therapeutic domains
- Advanced cell‑therapy and gene‑editing platforms enabling personalized oncology and immunology treatments
- Global clinical‑trial network and patient‑finder tools that streamline enrollment and data collection
- Strategic partnership program that collaborates with biotech, academic, and technology innovators to co‑develop breakthrough therapies
- Scalable biologics manufacturing and supply‑chain infrastructure ensuring consistent product quality and global availability
- Comprehensive regulatory and market‑access expertise to navigate approvals across major regions